• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$33.56 $0.21 (0.63%)

REAL-TIME: Last trade at

Charles River Laboratories

NYSE:CRL

Salix Beats; Ups EPS Outlook - Analyst Blog

Earnings Beat for CRL, Maintains View - Analyst Blog

Charles River Laboratories International Beats Analyst Estimates on EPS

The Zacks Analyst Blog Highlights: Eli Lilly, Pfizer, Johnson & Johnson, The TJX and Macy's - Press

FDA Approves Lilly's Amyvid - Analyst Blog

Here's How Charles River Laboratories International Is Making You So Much Cash

Still Neutral on Human Genome - Analyst Blog

Arena Pharma Drug under EU Review - Analyst Blog

Still Neutral on MannKind - Analyst Blog

Charles River Laboratories International Crushes Earnings Estimates

FDA Issues CRL for Watson's Drug - Analyst Blog

Salix Beats, Provides Mixed Guidance - Analyst Blog

MannKind Narrows Loss - Analyst Blog

ViroPharma Extends Buccolam's Reach - Analyst Blog

US STOCK FUTURES: HOT STOCKS TO WATCH

US STOCK FUTURES: HOT STOCKS TO WATCH

Upgrades & Downgrades: Nobody Doesn't Like Sara Lee

Update on VPHM's Industrial Facility - Analyst Blog

Novo Nordisk Posts Solid 4Q - Analyst Blog

Why Drug Development Company Charles River Laboratories Is Undervalued

Why Charles River Laboratories International May Be About to Take Off

MannKind Treads the Neutral Path - Analyst Blog

Bristol-Myers/AstraZeneca get CRL - Analyst Blog

Company News for January 11, 2012 - Corporate Summary

Charles River Shares Soared: What You Need to Know

Arena Pharma Files Response to CRL - Analyst Blog

Charles River Guides Higher - Analyst Blog

Good News for Endo Pharma - Analyst Blog

Don't Get Too Worked Up Over ICON's Earnings

Risk-Reward Balanced at Theravance - Analyst Blog

Smart Money Picks: Biotech Stocks With Bullish Short Trends

PPDI Shareholders Nod to Merger - Analyst Blog

MannKind in Neutral Lane - Analyst Blog

Are Shorts Watching Pharmaceutical Product Development?

Whoa! My Stock Just Whomped the Market!

1 Special Stock Pick From an Outside View

Here's How Covance Is Making You So Much Cash

Is ICON the Perfect Stock?

Charles River Laboratories International's CEO Discusses Q2 2011 Results - Earnings Call Transcript

Charles River Laboratories Earnings Preview

See More Articles...